US F.D.A. Approves Ivacaftor
Bravo to Vertex for bringing this to market. Molecules to address the genetic basis of a disease are incredibly expensive to develop and market.
Even though this only addresses one of the mutated genes (G551D) that cause Cystic Fibrosis, it brings hope. Respiratory illnesses are horribly painful and I hope that the relief this provides brings happiness to patients, their families and loved ones.
I’m sure that EMA approval is not far behind.